Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. - Wikidata - wikimedia - TriplyDB

Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice.

Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice.

http://www.wikidata.org/entity/Q46738149

about

Alzheimer's disease as homeostatic responses to age-related myelin breakdown The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein Impact of apolipoprotein E on Alzheimer's disease Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease ApoE promotes the proteolytic degradation of Abeta Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease The liver X receptor agonist GW3965 improves recovery from mild repetitive traumatic brain injury in mice partly through apolipoprotein E Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet Identification of a Chrysanthemic Ester as an Apolipoprotein E Inducer in Astrocytes Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance Role of Abca7 in mouse behaviours relevant to neurodegenerative diseases.ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.Alzheimer disease models and human neuropathology: similarities and differences Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial Opposing effects of Apoe/Apoa1 double deletion on amyloid-β pathology and cognitive performance in APP mice.Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle Metals and cholesterol: two sides of the same coin in Alzheimer's disease pathology.Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway.Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.Apolipoprotein E: from lipid transport to neurobiology Modulation of ABCA1 by an LXR agonist reduces β-amyloid levels and improves outcome after traumatic brain injury The role of apolipoprotein E in Alzheimer's disease.MicroRNAs: a connection between cholesterol metabolism and neurodegeneration.HDL and cognition in neurodegenerative disorders.Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.ABCA8 stimulates sphingomyelin production in oligodendrocytes.Juvenile traumatic brain injury induces long-term perivascular matrix changes alongside amyloid-beta accumulation.Domains of apoE4 required for the biogenesis of apoE-containing HDL.Atherosclerosis and Alzheimer--diseases with a common cause? Inflammation, oxysterols, vasculature Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist An ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from glia.Nuclear receptors as therapeutic targets for Alzheimer's disease Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles.Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels.

P2860

Q22251261-E86A2DF8-1ECD-42C5-AE59-C50F27A8C76C Q24296758-D3AC0F07-0638-4C35-A1DB-7D0ADA9F2A60 Q24567759-2CDA7E30-9D34-4632-A56D-681785D69537 Q24650450-7AA25BDD-DFC6-4E31-B745-4A2F72F514ED Q24651102-C030C194-72CC-4192-B52B-341401C542F2 Q26747482-ACF3DB36-4515-4297-B221-D6192D8B3E49 Q26858870-D3B988F2-0F71-4F37-980B-5390F988940F Q27321301-0ACE1CD2-3FE7-4F6C-A65F-090D2746E2C0 Q28071254-02EC6817-ACD7-44A2-899C-130DF0C051B7 Q28535014-E1CC5D1A-D403-465F-8080-DCB9422F4F80 Q28553918-598FBF59-83A1-4553-A2DF-03B51B3EB2B5 Q30274556-B9EADD1E-94C8-434F-8AE2-FA139DF3ABF8 Q30463254-81A15C87-5706-4E81-8507-9D0819344D3E Q30497102-05455D6F-A135-42EA-AB33-0A6F511627F1 Q30499574-34C83F22-D282-4453-AE65-71A5F738989C Q30559265-AA07D51C-AF53-41BE-9B4F-A965D8B98E4D Q30703354-C3868617-74A1-4271-ADB8-1A5B86D07B20 Q33584772-ECE138E4-56E8-4886-B1EC-7B21BEACC32B Q33646882-B471B902-DFD6-4681-86F9-4363991F7BE0 Q33676328-AAF317E6-4F4E-4410-BFA0-371CE08FED9B Q33906674-0849359E-38C9-498E-992E-15ABC8C54BD7 Q33945108-D4C1F096-5366-4066-974E-2B0DAA2562B4 Q34212267-5A0746B5-A45B-4809-BFB2-A2C1D696CC19 Q34299304-9AD97DDE-4347-479B-9A9A-4FF61027B509 Q34431008-72A365DD-D233-49C4-A51E-732FD3124B0B Q34497951-082AC786-7138-4753-A60B-A72868CC5209 Q34569187-DD995593-D0A9-42F8-B0FE-FA343F7CDBCF Q34603092-CF7A2BCE-ED3E-40F4-961A-3A103456BA3A Q34613640-C253431B-49DD-4AF7-A5AD-C295FA73637C Q34614842-9E42A647-E8DB-49AB-BEBC-D0A2899720E2 Q34621541-E4230F42-C309-4460-828E-3AE6BD3009F4 Q34656787-A2305AC4-AD01-4B09-9CC7-211B3BB60A7A Q34727104-47D42FD8-B809-4F26-8395-ECBECAC5B934 Q35031146-EFDA8B00-53B4-4B9C-938C-1F6237A5D3CA Q35127516-BFF9802B-994F-4365-A4C0-B4EF8D69EBDC Q35137114-175D43EC-DBF2-4EBD-BCD8-FBCCC830FC3F Q35152189-F694D7C6-5066-4215-8220-33B0B84A5122 Q35165186-76E441BF-D8F1-4BE1-838D-DC248D1FCB8E Q35664947-5EE160C7-7B66-422E-BF92-B4B5A1833079 Q35694025-FBCF2E5E-29F3-4546-82BF-314B73659ECB

P2860

Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice.

http://www.wikidata.org/entity/Q46738149

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Lack of ABCA1 considerably dec ...... loid deposition in APP23 mice.

@en

Lack of ABCA1 considerably dec ...... loid deposition in APP23 mice.

@nl

type

label

Lack of ABCA1 considerably dec ...... loid deposition in APP23 mice.

@en

Lack of ABCA1 considerably dec ...... loid deposition in APP23 mice.

@nl

prefLabel

Lack of ABCA1 considerably dec ...... loid deposition in APP23 mice.

@en

Lack of ABCA1 considerably dec ...... loid deposition in APP23 mice.

@nl

P1433

Q46738149-76E13E25-0C95-4F6A-B673-B12F7AA05683

P1476

Q46738149-D3ACD2BE-E698-47A5-8319-57B77A80068E

P2093

Q46738149-0E8A7B9E-6F20-47EB-AE6D-8509DCDF6E20

P2860

Q46738149-019B4995-3E58-479A-A88D-959CFE62C175

Q46738149-01F9B2AD-D53E-46F5-B171-462E067A28C8

Q46738149-0807EC57-299E-4D79-8352-7A8EF5F3F1FB

Q46738149-09D9D50C-9A12-4E0E-9BBF-E4DACD6EFA25

Q46738149-13E396ED-01FF-4DD5-9371-75E12F0444E6

Q46738149-14F801DD-2EBB-4F8D-96FD-E1C79D0299B0

Q46738149-153FF594-4261-45D4-A586-D39F5DE3D680

Q46738149-1DB66FD5-F3BD-48D7-942B-5651A56ACDA8

Q46738149-2258AEAA-E955-4DE3-A3E0-CAE4D4FEDC1C

Q46738149-27130257-DA43-4765-8212-CC7201574DE1

P304

Q46738149-0C4185B3-ABA3-4A25-B18E-38FB6945F0F8

P31

Q46738149-090D300E-BE80-49C8-82AE-7581F10384BA

P356

Q46738149-B553AFFD-6C98-445C-800C-FC1CC7FC3970

P407

Q46738149-C723782F-697C-4B1E-8CC1-F3698FFF4CED

P433

Q46738149-98A6EF31-89A8-4268-BF9C-04F5A478FF2D

P478

Q46738149-B5593DE8-E898-49AA-A805-C67810734436

P50

Q46738149-06AE28E4-2F40-445F-A1B8-068BEF03D960

Q46738149-BFC649FA-5D0D-4F30-A0A9-AF897F0AC9B9

P577

Q46738149-66910FEC-FCD4-4B33-A6BE-EEA71F12EB2C

P698

Q46738149-68AD06FF-4C75-4B53-820B-A91245CE2070

P356

P1433

Journal of Biological Chemistry

P1476

Lack of ABCA1 considerably dec ...... loid deposition in APP23 mice.

@en

P2093

Iliya Lefterov

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity

The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease

Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1

Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase

Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene

Differential expression of cholesterol hydroxylases in Alzheimer's disease

The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease

Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity

P304

43224-43235

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M504513200

http://www.w3.org/2001/XMLSchema#string

P407

P433

52

http://www.w3.org/2001/XMLSchema#string

P478

280

http://www.w3.org/2001/XMLSchema#string

P50

Radosveta Koldamova

Matthias Staufenbiel

P577

2005-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16207713

http://www.w3.org/2001/XMLSchema#string